AV-101-002 (IMPAHCT)

By /
Return to Clinical Trials
Listing Category
Description


A Phase 2b/3, Randomized, Double-Blind, Placebo- Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hypertension (PAH)

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Study Details
Principal Investigator
Dr. John Swisher, StatCare Medical Group
Scroll to Top